Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dyspnea, Lactic Acidosis, Muscle, Breathlessness, Exercise, Recovery
Interventions: High Velocity Therapy; Device
Lead sponsor: Vapotherm, Inc.; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Cardiovascular Disease
Interventions: Vascular surgery with best medical treatment, Coronary artery bypass grafting (CABG), Percutaneous transluminal coronary angioplasty (PTCA); Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 18
States / cities: Tucson, Arizona • No. Little Rock, Arkansas • San Francisco, California + 15 more

Conditions: Breast Cancer, Adenocarcinoma of the Breast
Interventions: epirubicin, cyclophosphamide, Paclitaxel,; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 95 Years · Male only
Enrollment: 60 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Transplant; Complications, Perioperative/Postoperative Complications
Interventions: Cadaveric, Living Donor; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma, Bithalamic High Grade Glioma, Brainstem Glioma, Glioblastoma, Anaplastic Astrocytoma
Interventions: ribociclib, Everolimus; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Months to 30 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Charlotte, North Carolina + 4 more

Conditions: Carcinoma of Unknown Primary, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma of the Skin
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Hospitalization, Patient Readmission
Interventions: Provision of extra (care coordination and management) services; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 64 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: radiation therapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypoxemic Respiratory Failure, Airway Obstruction
Interventions: nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen, standard jet nebulization (SJN) with face mask; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: fludarabine phosphate, triapine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Houston, Texas

Conditions: Prostate Cancer
Interventions: High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 4
States / cities: Columbus, Ohio • Houston, Texas • Seattle, Washington

Conditions: Lung Cancer
Interventions: Induction Carboplatin, Induction Paclitaxel, Resection, Consolidation Carboplatin, Radiation Therapy, Consolidation Paclitaxel; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more

Conditions: Recurrent Neuroblastoma
Interventions: fenretinide, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Healthy
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Mental Health Disorder
Interventions: Arena Strive, Control Cohort; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Amyotrophic Lateral Sclerosis, Respiratory Muscle Weakness
Interventions: High Frequency Chest Wall Oscillation, Mechanical insufflation/exsufflation; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glioma
Interventions: RTA 744, RTA 744 injection; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 4
States / cities: Los Angeles, California • Dallas, Texas • Houston, Texas

Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions: Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab; Biological · Drug
Lead sponsor: Tocagen Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more

Conditions: Type2 Diabetes
Interventions: High Intensity Body-weight Circuit Training (HIBC); Behavioral
Lead sponsor: Kennesaw State University; Other
Eligibility: 45 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Gonorrhea
Interventions: Listerine Antiseptic Mouthwash Product, Biotene Mouthwash; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

High-resolution Phosphocreatine and Creatine Mapping of Human Muscle and Brain

Effect of High Velocity/Hyperoxic Breathing Therapy on Blood Lactate Decline

Does Prophylactic Coronary Artery Revascularization for High Risk Patients Reduce Long-term Risk of Mortality

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

Impact of Age and BMI on Liver Transplant Outcomes

A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors

CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer

Intervening With and Improving Care for Patients at Risk for Frequent Hospital Admissions

Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer

In Line Aerosol Nebulization With High Flow

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

High-field Brain Magnetic Resonance Spectroscopy

Arena Labs - Improving Clinician Well Being

ALS and Airway Clearance (ALSAC) Therapy

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

High Intensity Body-weight Circuit Training in Type 2 Diabetics

Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention